Stockscreener 앱 받기
19.19
1.59%
-0.31
시간 외 거래:
19.08
-0.11
-0.57%
Neurogene Inc 주식(NGNE)의 최신 뉴스
Neurogene Inc: chief scientific officer Cobb sells $141k in stock - Investing.com
Insider Selling: Neurogene (NASDAQ:NGNE) CFO Sells 4,045 Shares of Stock - MarketBeat
Neurogene (NGNE) CSO sells 6,797 shares under 10b5-1 plan - Stock Titan
Tax-driven share sale by Neurogene (NGNE) president and CFO disclosed - Stock Titan
Published on: 2026-03-17 03:31:12 - baoquankhu1.vn
Neurogene (NGNE) Expected to Announce Quarterly Earnings on Monday - MarketBeat
[144] Neurogene Inc. SEC Filing - Stock Titan
Neurogene to Participate in Stifel 2026 Virtual CNS Forum - Bluefield Daily Telegraph
Genetic-medicine firm Neurogene in Stifel 2026 virtual CNS fireside chat - Stock Titan
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
NGNE: Durable functional gains in Rett syndrome drive NGN-401's pivotal trial and commercial plans - TradingView
NGNE: NGN-401 shows durable, multi-domain gains in Rett syndrome, with pivotal data expected mid-2024 - TradingView
Gains Recap: Whats the analyst consensus on Neurogene Inc2026 Market Sentiment & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Will Neurogene Inc. stock outperform value stocksInsider Buying & Accurate Buy Signal Alerts - Naître et grandir
Aug Update: How correlated is Neurogene Inc to the S P500Chart Signals & Community Consensus Trade Alerts - baoquankhu1.vn
Layoff Watch: Is Neurogene Inc part of any major indexJuly 2025 PostEarnings & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Aug Movers: Is Neurogene Inc backed by strong institutional buyingJuly 2025 Breakouts & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Macro Review: Is Neurogene Inc in a long term uptrend2025 Market WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
Neurogene Inc. (NGNE) CFO sells 4,800 shares under 10b5-1 plan - Stock Titan
Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
Analysts Are Bullish on Top Healthcare Stocks: Mesoblast Limited (MEOBF), Neurogene (NGNE) - The Globe and Mail
Yatsen Holding, Delta Air Lines, United Airlines And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
NGNE SEC FilingsNeurogene 10-K, 10-Q, 8-K Forms - Stock Titan
Should You Buy Neurogene Inc (NGNE) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Neurogene: Stock Soars On FDA Designation For Rett Gene TherapyI'd Remain Cautious - Seeking Alpha
Canaccord Genuity Initiates Coverage of Neurogene (NGNE) with Buy Recommendation - Nasdaq
Neurogene (NASDAQ:NGNE) Now Covered by Canaccord Genuity Group - MarketBeat
This $20 Biotech Stock Just Got An FDA Boost – And A $200 Price Target - Stocktwits
FDA grants breakthrough therapy status to Neurogene’s Rett drug - Investing.com India
Why Is Neurogene Stock Skyrocketing Friday?Neurogene (NASDAQ:NGNE) - Benzinga
Neurogene : NGNE - 24/7 Wall St.
Neurogene Inc (ticker: NGNE) shares surged 32% in pre-market trading after the company announced that its experimental therapy for rare neurological diseases has received "Breakthrough Therapy" designation from the U.S. Food and Drug Administration (F - Bitget
Neurogene Gets FDA Breakthrough Tag For NGN-401 In Rett Syndrome; Stock Up - Nasdaq
FDA grants breakthrough therapy status to Neurogene’s Rett drug By Investing.com - Investing.com Australia
Neurogene Gains FDA Breakthrough Status for Rett Gene Therapy - TipRanks
Neurogene stock surges 30% on FDA breakthrough therapy status - Investing.com
Neurogene stock surges 30% on FDA breakthrough therapy status By Investing.com - Investing.com Australia
Neurogene Inc. wins FDA Breakthrough Therapy Designation for NGN-401 gene therapy - Traders Union
Neurogene Stock Soars On FDA Breakthrough Tag For Rett Gene Therapy - Bitget
Neurogene announces FDA breakthrough therapy designation for NGN-401 gene therapy for Rett syndrome - marketscreener.com
FDA grants Breakthrough status to Neurogene (NGNE) Rett gene therapy - Stock Titan
FDA fast-tracks one-time Rett syndrome gene therapy from Neurogene - Stock Titan
Neurogene Inc. (NGNE) Stock Analysis: Exploring a Potential 184.72% Upside in the Biotech Sector - DirectorsTalk Interviews
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome - Weekly Voice
NGNE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Neurogene Inc. (NGNE) CSO awarded 16,500 restricted stock units - Stock Titan
Neurogene (NGNE) CMO receives new stock option and RSU grants - Stock Titan
[Form 4] Neurogene Inc. Insider Trading Activity - Stock Titan
Neurogene (NGNE) grants 12,050 non-qualified stock options to director Palekar - Stock Titan
Director at Neurogene (NGNE) granted 12,050 non-qualified stock options - Stock Titan
Neurogene (NGNE) director receives grant of 12,050 non-qualified options - Stock Titan
Neurogene Inc. (NGNE): Investor Outlook With A 232% Potential Upside - DirectorsTalk Interviews
Aug Analyst Calls: What is the earnings history of Neurogene IncJuly 2025 Action & Long-Term Investment Growth Plans - baoquankhu1.vn
Redmile discloses 9.9% Neurogene (NGNE) ownership stake via warrants and shares - Stock Titan
Is Neurogene Inc. stock near bottom after declineEarnings Overview Report & Safe Capital Growth Stock Tips - mfd.ru
Is Neurogene Inc. a potential multi baggerWeekly Profit Summary & Technical Buy Zone Confirmations - mfd.ru
How sensitive is Neurogene Inc. to inflationEntry Point & Reliable Price Breakout Alerts - mfd.ru
Can Neurogene Inc. outperform under higher oil pricesJuly 2025 Catalysts & Accurate Intraday Trade Tips - mfd.ru
How Neurogene Inc. stock reacts to oil prices2025 Key Highlights & Expert Approved Trade Ideas - mfd.ru
Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit - Yahoo Finance
Aug Shorts: Whats the analyst consensus on Neurogene IncWeekly Investment Recap & Accurate Buy Signal Alerts - baoquankhu1.vn
1.20%
0.06%
자본화:
|
볼륨(24시간):